JOURNAL ARTICLE
REVIEW
Add like
Add dislike
Add to saved papers

Gonadotropin-releasing hormone agonists: strategies for managing the hypoestrogenic effects of therapy.

Gonadotropin-releasing hormone agonists have been shown to be comparable with danazol for the treatment of endometriosis. These results are important because danazol is associated with a significant number of side effects, particularly androgenic effects, such as weight gain and acne. Although gonadotropin-releasing hormone agonists are associated with hypoestrogenic side effects, such as hot flashes and reversible bone density loss, recent studies suggest that the risk of these side effects may be modified when gonadotropin-releasing hormone agonists are combined with a progestin. These findings suggest that such regimens may further enhance the clinical usefulness of gonadotropin-releasing hormone agonist therapy for endometriosis and other estrogen-mediated diseases.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

For the best experience, use the Read mobile app

Mobile app image

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

By using this service, you agree to our terms of use and privacy policy.

Your Privacy Choices Toggle icon

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app